imatinib mesylate has been researched along with Leucocythaemia in 172 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 99 (57.56) | 29.6817 |
| 2010's | 63 (36.63) | 24.3611 |
| 2020's | 10 (5.81) | 2.80 |
| Authors | Studies |
|---|---|
| Akuthota, P; Kovalszki, A; Kwon, N; Requena, G; Steinfeld, J; van den Bosch, J; Van Dyke, MK | 1 |
| Liu, XL; Zhang, JF; Zong, S | 1 |
| Agarwal, DK; Ahsan, MJ; Jadav, SS; Khalilullah, H; Khan, MA; Khan, R; Mohammed, HA; Mohammed, SAA | 1 |
| He, BS; Hu, R; Li, Y; Liu, ML; Ruan, XL; Wang, B; Wang, J; Yang, YH; Zhu, J | 1 |
| Gamachi, A; Nagamatsu, K; Ono, K; Yanai, Y | 1 |
| Assouline, S; Brümmendorf, TH; Castagnetti, F; Cortes, JE; Gambacorti-Passerini, C; Kota, V; Leip, E; Lipton, JH; Viqueira, A | 1 |
| Botella-Estrada, R; de Unamuno-Bustos, B; Navarro-Mira, MÁ; Torres-Navarro, I | 1 |
| Chen, Y; Cheng, Z; Luo, Y; Peng, H; Wang, Y; Xu, Y; Zhang, G; Zhang, Y | 1 |
| Cai, D; Li, P; Lin, D; Wang, D; Yang, X; Zhang, Y; Zhang, Z | 1 |
| Fukuhara, N; Hirasawa, T; Kikuchi, M; Maekawa, M; Mano, N; Ogura, J; Onishi, Y; Onodera, K; Sato, T; Sato, Y; Shigeta, K; Takasaki, S | 1 |
| Alberich-Jorda, M; Doktorova, E; Falkenburg, JHF; Kanderova, V; Kuzilkova, D; Petrak, J; Starkova, J; Strnad, H; Stuchly, J; Trka, J; Zaliova, M; Zimmermannova, O; Zuna, J | 1 |
| Choi, CW; Kim, DS; Lee, S | 1 |
| Gong, YP; Guo, Y; Lin, J; Shan, QQ; Wang, YS | 1 |
| Huang, G; Li, J; Qin, T; Qu, S; Wang, Q; Xiao, Z; Xu, Z; Zhang, Y | 1 |
| Craig, D; Edirisinghe, M; Karimpoor, M; Khorashad, JS; Orlu, M; Parhizkar, M; Yebra-Fernandez, E | 1 |
| Ai, XF; Fang, LW; Hu, NB; Jia, YJ; Li, B; Liu, JQ; Pan, LJ; Qin, TJ; Qu, SQ; Ru, K; Xiao, ZJ; Xu, ZF; Zhang, HL; Zhang, Y | 1 |
| Guo, XZ; Guo, YF; Pan, JX; Wu, SX; Zhang, XY | 1 |
| Bärnthaler, T; Frank, S; Grill, M; Heinemann, A; Jandl, K; Marsche, G; Schicho, R; Schreiber, Y; Schuligoi, R; Sill, H; Thomas, D; Uhl, B | 1 |
| Alam, H; Nazir, L; Riaz, A | 1 |
| Grandori, C; Kemp, CJ | 1 |
| Mandavilli, A | 1 |
| Baldwin, AS; Christopherson, RI; Cooper, MJ; Cox, NJ; Dewar, BJ; Duncan, JS; Frye, SV; Ghose Roy, S; Graves, LM; Jin, J; Johnson, GL; Jones, LS; Kuan, PF; Nguyen, TA; Richards, KL; Smalley, DM; Whittle, MC; Zimmerman, EI | 1 |
| Bertomeu, T; Bucur, O; Dewar, R; Goganau, I; Khosravi-Far, R; Pennarun, B; Petrescu, SM; Stancu, AL | 1 |
| Bottaro, DP; Burke, TR; Croce, CM; Liu, H; Luo, Z; Zhang, M | 1 |
| Ågerstam, H; Ehrencrona, H; Fioretos, T; Lilljebjörn, H; Nilsson, L; Orsmark-Pietras, C; Richter, J; Rissler, M | 1 |
| Beghini, A; Cassin, R; Cortelezzi, A; Ferla, V; Fracchiolla, NS; Gianelli, U; Gottardi, E; Iurlo, A; Spinelli, O | 1 |
| Demoulin, JB; Essaghir, A | 1 |
| Cross, NC; Erben, P; Fabarius, A; Gosenca, D; Haferlach, C; Haferlach, T; Hofmann, WK; Kellert, B; Kneba, M; Metzgeroth, G; Reiter, A; Scheid, C; Schwaab, J; Seifarth, W; Töpelt, K | 1 |
| Kanashima, H; Murakami, A; Nakao, T; Tamagawa, N; Ueda, H; Yamane, T; Yorifuji, T; Yoshida, M | 1 |
| Beghini, A; Cambiaghi, S; Cortelezzi, A; Gianelli, U; Intermesoli, T; Iurlo, A; Lazzaroni, F; Orofino, N; Rambaldi, A; Spinelli, O | 1 |
| Chandía, M; Torres C, D | 1 |
| Ding, K; Pan, J; Ren, X; Shen, Y; Wang, D; Zhang, Z | 1 |
| Cao, J; Chen, C; Han, ZX; Li, ZY; Lu, XY; Pan, B; Qiao, JL; Song, XG; Wang, L; Wang, M; Wu, QY; Xu, KL; Yan, ZL; Zeng, LY; Zhang, HX; Zhao, K; Zhu, P | 1 |
| Ali, SM; Campregher, PV; Chalmers, ZR; Chmielecki, J; Elvin, JA; Erlich, R; Frampton, GM; Hermann, R; Miles, CR; Miller, VA; Ohgami, RS; Palma, NA; Ross, JS; Stephens, PJ; Vergilio, JA; Yelensky, R | 1 |
| Ai, HS; Dong, Z; Guo, M; Hu, KX; Li, BX; Qiao, JH; Sun, QY; Yao, B; Yu, CL; Zhang, ZC | 1 |
| Guo, S; Huang, A; Kelly, DF; Liang, Y; Murphy, SF; Shen, H; Sheng, Z; Sobrado, P | 1 |
| Baird, K; Booher, S; Comis, LE; Cowen, EW; Figg, WD; Flanders, KC; Hakim, FT; Joe, GO; Mitchell, SA; Pavletic, SZ; Rose, JJ; Sarantopoulos, S; Steinberg, SM; Takebe, N; Yao, L | 1 |
| Géraud, C; Goerdt, S; Marx, A; Peitsch, WK; Reiter, A; Ziegler, B | 1 |
| Falchi, L; Verstovsek, S | 1 |
| Roufosse, F | 1 |
| Katayama, N; Masuya, M; Matsui, T; Monma, F; Nobori, T; Ohishi, K; Sada, A; Shimokariya, Y; Sugimoto, Y | 1 |
| Feng, S; Han, M; He, Y; Liu, Q; Shi, Y; Yang, D; Zhang, R | 1 |
| Fassnacht, F; Fouret, P; Kahn, JE; Lefevre, G; Levy, V; Roumier, M; Russel, S; Varnous, S | 1 |
| Hayakawa, K; Komatsu, T; Tanimoto, T; Tsuda, K | 1 |
| Oshima, Y; Tojo, A; Yuji, K | 1 |
| Ai, XF; Fang, LW; Hu, NB; Li, B; Pan, LJ; Qin, TJ; Qu, SQ; Xiao, ZJ; Xu, ZF; Zhang, HL; Zhang, Y | 1 |
| Bron, D; Cordier, JF; Cottin, V; Heimann, P; Lambert, F; Roufosse, F; Sidon, P | 1 |
| Hayakawa, F; Kato, H; Miyata, Y; Mizuno, H; Nakayama, T; Naoe, T; Nishiwaki, S; Saito, S; Sugimoto, K; Suzuki, R; Takami, A; Takeshita, K; Ueda, R | 1 |
| Andrews, LM; Atiq, F; Broers, AE; Doorduijn, JK; Koch, BC; Van Gelder, T; Versmissen, J | 1 |
| Árvai, K; Balla, B; Horváth, P; Kirschner, G; Kósa, J; Kövesdi, A; Lakatos, G; Lakatos, P; Nagy, Z; Takács, I; Tóbiás, B | 1 |
| Deininger, MW; Druker, BJ; Honigberg, LA; MacPartlin, M; Smith, AM | 1 |
| Bullinger, L; Chen, J; Fröhling, S; Gilliland, DG; Golub, TR; Gu, TL; Lee, BH; Monti, S; Tam, WF; Wang, A | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Kornbluth, S; Kurokawa, M; Reya, T; Zhao, C | 1 |
| Becker, H; Berg, T; Binder, M; Dierks, C; Duque-Afonso, J; Hackanson, B; Lairmore, MD; Lübbert, M; Martens, U; Mertelsmann, R; Schäfer, HS; Schnitzler, M; Zeiser, R | 1 |
| Adachi, S; Endo, M; Fujino, H; Ito, E; Kanezaki, R; Sato, T; Suzuki, K; Tauchi, H; Toki, T; Xu, G | 1 |
| Kolb, HJ | 1 |
| de Revel, T; Fagot, T; Konopacki, J; Malfuson, JV; Mangouka, L; Souleau, B | 1 |
| Anderson, N; Christians, U; Eckhardt, SG; Klawitter, J; Leibfritz, D; Serkova, NJ | 1 |
| Gu, Y; Ma, T; Qiu, X; Xie, J; Xu, R; Yu, Y; Zhang, L; Zhang, X | 1 |
| Dührsen, U; Ebeling, P; Jansen, JH; Khandanpour, C; Mahlmann, S; Möröy, T; van der Reijden, BA; Vassen, L | 1 |
| Doi, Y; Hasegawa, H; Kamihira, S; Matsuo, E; Miyazaki, Y; Mori, S; Nagai, K; Sasaki, D; Terada, C; Tsuruda, K; Yamada, Y; Yanagihara, K | 1 |
| Dewar, MR; Ghaffari, S; Grassian, A; Jagani, Z; Khosravi-Far, R; Kutok, JL; Melet, A; Miller, K; Ren, R; Rodin, HY; Santos, T; Song, K; Wu, C; Yeckes-Rodin, H | 1 |
| Dingli, D; Pacheco, JM; Traulsen, A | 1 |
| Beelen, DW; Elmaagacli, AH; Koldehoff, M; Kordelas, L | 1 |
| Wang, Y; Yang, Z; Zhao, X | 1 |
| Berdel, WE; Cross, NC; Elling, C; Erben, P; Frickenhaus, M; Hochhaus, A; Hofmann, WK; Koschmieder, S; Müller-Tidow, C; Reiter, A; Schemionek, M; Serve, H; Stehling, M; Walz, C | 1 |
| Kawasaki, Y; Nakazora, T; Shinohara, K; Suzukawa, M; Tominaga, T | 1 |
| Akahane, K; Goi, K; Hirose, K; Honna, H; Inukai, T; Kagami, K; Kuroda, I; Sugita, K; Tauchi, T; Yagita, H; Zhang, X | 1 |
| Bergamini, C; Bonifacio, M; Carcereri de Prati, A; Cavalieri, E; Fato, R; Guardalben, E; Pizzolo, G; Rigo, A; Suzuki, H; Vinante, F | 1 |
| Belinka, BA; Gupta, A; Kachlany, SC; Le, A | 1 |
| Balayssac, S; Ballot, C; Briand, G; Dammak, A; Dauphin, V; Formstecher, P; Idziorek, T; Jendoubi, M; Joha, S; Jonneaux, A; Kluza, J; Maboudou, P; Malet-Martino, M; Marchetti, P; Quesnel, B | 1 |
| Kutner, A; Maciejewska, M; Nasulewicz-Goldeman, A; Opolska, A; Switalska, M; Wietrzyk, J | 1 |
| Hegde, AH; Punith, R; Seetharamappa, J | 1 |
| Barber, DL; Der, S; Gillis, LC; Huang, K; Jarvis, JD; Kim, H; Yang, S | 1 |
| Esmailzadeh, S; Jiang, X | 1 |
| Beumer, JH; Bose, P; Colevas, AD; Cooper, BW; Douglas Figg, W; Egorin, MJ; Grant, S; Honeycut, C; Imamura, CK; Jacobberger, JW; Karp, JE; Koc, ON; Kontopodis, E; Luger, SM; Perkins, EB; Roberts, JD; Stefan, T; Wellons, MD | 1 |
| Kuo, CC; Lee, CM; Lin, LC; Wang, LS; Wu, AT; Wu, CH; Yang, WC; Yeh, CT; Yen, GC | 1 |
| Cho, SG; Choi, HY; Kang, GH; Kim, JH; Kim, Y; Koo, BN; Lee, C; Lee, ER; Song, M | 1 |
| Dingermann, T; Marschalek, R; Zündorf, I | 1 |
| Caliceti, C; Fiorentini, D; Hakim, G; Hrelia, S; Prata, C; Vieceli Dalla Sega, F; Zambonin, L | 1 |
| Akahane, K; Fujimoto, J; Goi, K; Hirose, K; Honna-Oshiro, H; Inaba, T; Inukai, T; Kagami, K; Kiyokawa, N; Miyagawa, Y; Nakazawa, S; Nemoto, A; Sato, H; Sugita, K; Takahashi, K; Uno, K | 1 |
| Bringmann, A; Brossart, P; Driessen, C; Duchardt, KM; Heine, A; Held, SA; Kurts, C; Rückrich, T; Schild, H; Tenzer, S; von Schwarzenberg, K | 1 |
| Attkisson, E; Dasmahapatra, G; Grant, S; Nguyen, T; Patel, H | 1 |
| Deininger, MW; Ito, T; Kornbluth, S; Kurokawa, M; Macintyre, AN; Rathmell, JC; Reya, T; Rizzieri, DA; Yang, CS; Zhao, C | 1 |
| Abolfazli, R; Harirchian, MH; Siroos, B | 1 |
| Luzzatto, L; Melo, JV | 1 |
| Borkhardt, A; Fuchs, U; Wilda, M; Wössmann, W | 1 |
| Buchdunger, E; Fabbro, D; Forster, K; Hallek, M; Manley, PW; Mathes, R; Mitina, O; Moarefi, I; Simon, N; Warmuth, M | 1 |
| Abe, K; Nakajima, A; Ohyashiki, JH; Ohyashiki, K; Sashida, G; Shimamoto, T; Tauchi, T; Yamamoto, K | 1 |
| Belloc, F; Chollet, C; Goldman, JM; Lagarde, V; Mahon, FX; Melo, JV; Moreau-Gaudry, F; Reiffers, J | 1 |
| Courtneidge, SA | 1 |
| Beissert, T; Bianchini, A; Boehrer, S; Güller, S; Hoelzer, D; Nervi, C; Ottmann, OG; Puccetti, E; Ruthardt, M | 1 |
| Stull, DM | 1 |
| Rothberg, PG | 1 |
| Ueda, R | 1 |
| Griffin, JD; Sattler, M; Scheijen, B; Weisberg, E | 1 |
| George, D | 1 |
| Huang, F; Liu, XL; Meng, FY; Song, LL; Xu, B; Zhang, Y; Zheng, WY | 1 |
| Binckebanck, A; Brück, P; Gökbuget, N; Gschaidmeier, H; Hoelzer, D; Hofmann, WK; Komor, M; Leimer, L; Lübbert, M; Ottmann, OG; Pfeifer, H; Scheuring, U; Schleyer, E; Wassmann, B; Wolff, T | 1 |
| Bourgeois, E; Cambier, N; Dupire, S; Grardel, N; Preudhomme, C; Roche-Lestienne, C; Rose, C | 1 |
| Chen, L; Fei, XH; Gao, L; Huang, ZX; Lou, JW; Wang, JM; Xu, XP | 1 |
| Baldetorp, B; Fioretos, T; Gullberg, U; Håkansson, P; Karlsson, A; Lassen, C; Olofsson, T | 1 |
| Coutré, S; Gotlib, J | 1 |
| Boulton, C; Gilliland, DG; Griffin, JD; Gu, TL; Mohi, MG; Neel, BG; Neuberg, D; Sternberg, DW | 1 |
| Kimura, S; Kuroda, J; Maekawa, T; Nogawa, M; Ottmann, OG; Sato, K; Segawa, H; Yuasa, T | 1 |
| Duffy, KM | 1 |
| Ohyashiki, K; Tauchi, T | 1 |
| Kees, UR | 1 |
| Błasiak, J; Czechowska, A | 1 |
| Bornhäuser, M; Braess, J; Ehninger, G; Freiberg-Richter, J; Illmer, T; Köhne, Ch; Le Coutre, P; Ottmann, OG; Platzbecker, U; Pursche, J; Schaich, M; Schleyer, E; Thiede, C; von Bonin, M | 1 |
| Kakihana, K; Kurosu, T; Miura, O; Mizuchi, D; Yamamoto, M | 1 |
| Bernstein, M; Blaney, SM; Capdeville, R; Champagne, MA; Krailo, M; Peng, B; Qu, W; Rosamilia, M; Therrien, M; Zoellner, U | 1 |
| Wiernik, PH | 1 |
| Matsunaga, T; Niitsu, Y | 1 |
| Douek, DC; Dunbar, CE; Greiner, E; Loré, K; Magnusson, MK; Price, DA; Seggewiss, R; Wiestner, A | 1 |
| Beghini, A; Cairoli, R; Grillo, G; Larizza, L; Montillo, M; Morello, E; Morra, E | 1 |
| Dusková, M; Jelínek, F; Ludvíková, V; Marinov, I; Petrácková, M; Smetana, K; Sobotkova, E; Vonka, V | 1 |
| Mlejnek, P | 1 |
| Majsterek, IJ | 1 |
| Kano, Y; Komatsu, N; Miyoshi, T; Muroi, K; Nagai, T; Nakamura, M; Ohmine, K; Ozawa, K | 1 |
| Heinemann, V; Hiddemann, W | 1 |
| Asaki, T; Ashihara, E; Hirabayashi, K; Kamitsuji, Y; Kawata, E; Kimura, S; Kuroda, J; Maekawa, T; Naito, H; Nakaya, Y; Naruoka, H; Nasu, K; Niwa, T; Sato, K; Segawa, H; Wakayama, T; Yokota, A; Yuasa, T | 1 |
| Blaser, BW; Bloomfield, CD; Bruner-Klisovic, R; Caligiuri, MA; Chang, JS; Galietta, A; Liu, S; Mao, H; Marcucci, G; Neviani, P; Notari, M; Perrotti, D; Roy, DC; Santhanam, R; Trotta, R; Uttam, A; Valtieri, M | 1 |
| Beran, M; Bhalla, K; Chandra, J; Donato, N; Estrov, Z; Flatten, K; Gorre, M; Karp, J; Kaufmann, SH; Loegering, D; Sausville, E; Sawyers, C; Talpaz, M; Tracy, J; Verstovsek, S | 1 |
| Biard-Piechaczyk, M; Denizot, M; Espert, L; Grimaldi, M; Robert-Hebmann, V | 1 |
| Kimura, S; Maekawa, T | 1 |
| Atadja, P; Balasis, M; Bali, P; Bhalla, K; Boyapalle, S; Fiskus, W; Giles, F; Kumaraswamy, S; Manley, PW; Pranpat, M; Rocha, K; Wu, J | 1 |
| Hirabayashi, K; Ito, S; Kimura, S; Maekawa, T; Naito, H; Nakaya, Y; Naruoka, H; Wakayama, T | 1 |
| Boqué, C; Brand, R; Deininger, M; Doelken, G; Druker, B; Faber, E; Fauser, A; Fischer, T; Gratwohl, A; Greinix, H; Hochhaus, A; Iacobelli, S; Kiehl, M; Kolb, H; Krahl, R; Lange, T; Martinez, J; Maziarz, R; Nagler, A; Niederwieser, D; Olavarria, E; Pogliani, E; Russell, N; Sayer, HG; Schaefer, K; Schanz, U; Schleuning, M; Sureda, A; Verdonck, L; Volin, L | 1 |
| Corbin, AS; Dent, P; Druker, BJ; Gao, N; Grant, S; Kramer, L; Nguyen, TK; Rahmani, M | 1 |
| Bornmann, WG; Cepero, E; Clarkson, B; de Stanchina, E; Emig, M; Fridman, JS; Hochhaus, A; Kogan, SC; Lowe, SW; McCombie, WR; Ray, S; Veach, DR; Wendel, HG | 1 |
| Gong, FJ; Li, RJ; Zhang, GS | 1 |
| Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Kobayashi, H; Mano, H; Tsunoda, S | 1 |
| Kanakura, Y; Matsumura, I | 1 |
| Burgess, MR; Sawyers, CL | 1 |
| Abraham, A; Gastl, G; Gust, R; Kircher, B; Ott, I; Schumacher, P; Shorafa, H | 1 |
| Balabanov, S; Bokemeyer, C; Brassat, U; Brümmendorf, TH; Copland, M; Gontarewicz, A; Hartmann, U; Hauber, I; Hauber, J; Holyoake, TL; Kammer, W; Kanz, L; Nordheim, A; Priemer, M; Schwarz, G; Wilhelm, T; Ziegler, P | 1 |
| Banerji, L; Callahan, L; Catley, L; DellaGatta, JL; Fabbro, D; Griffin, JD; Hall-Meyers, E; Jiang, J; Kung, AL; Manley, PW; Mestan, J; Moreno, D; Ray, A; Weisberg, E; Wright, RD | 1 |
| Abe, A; Borkhardt, A; Fuchs, U; Herzog, S; Jumaa, H; Köhler, F; Kulathu, Y; Meixlsperger, S; Mittler, G; Wossning, T | 1 |
| Argilagos, RF; Dalton, WS; Hazlehurst, LA | 1 |
| Glauche, I; Horn, M; Roeder, I | 1 |
| Chen, H; Han, W; Huang, XJ; Liu, DH; Liu, KY; Xu, LP | 1 |
| Hughes, TP; Manley, PW; Quinn, SR; Saunders, VA; White, DL | 1 |
| Nieborowska-Skorska, M; Reiss, K; Rink, L; Seferynska, I; Skorski, T; Slupianek, A; Stoklosa, T; Urbanska, K | 1 |
| Dazzi, F; Fozza, C | 1 |
| Okuda, T | 1 |
| Bernhard, H; Duyster, J; Peschel, C; Scheich, F | 1 |
| Armstrong, SA; Stubbs, MC | 1 |
| Chen, GQ; Wang, LS; Wu, YL; Yu, Y | 1 |
| Chen, SJ; Chen, Z; Li, G; Zhou, GB | 1 |
| Mitani, K | 1 |
| Furuyama, K; Kikuchi, S; Komatsu, N; Kondo, T; Miyoshi, T; Nagai, T; Nakamura, M; Ohmine, K; Ozawa, K | 1 |
| Corm, S; Deluche, L; Geffroy, S; Joha, S; Laï, JL; Nicolini, FE; Philippe, N; Preudhomme, C; Roche-Lestienne, C; Tigaud, I | 1 |
| Biollaz, J; Décosterd, LA; Fayet, A; Lahrichi, SL; Pesse, B; Rochat, B; Widmer, N | 1 |
| Brussolo, S; Cleris, L; Donella-Deana, A; Drueckes, P; Formelli, F; Gambacorti-Passerini, C; Gunby, RH; Kubbutat, M; Lucchini, V; Marchesi, E; Mologni, L; Moretti, L; Puttini, M; Redaelli, S; Sala, E; Scapozza, L; Zambon, A | 1 |
| Chen, YZ; Huang, XW; Lin, Q; Wen, CX; Wu, LX; Xu, JH; Zhang, KZ | 1 |
| Grossbard, ML | 1 |
| Bhalla, KN; Fang, G; Kim, CN; Perkins, CL; Ramadevi, N; Winton, E; Wittmann, S | 1 |
| Stephenson, J | 1 |
| Bhalla, K; Nguyen, D; Nimmanapalli, R; O'Bryan, E; Perkins, C; Porosnicu, M; Worthington, E | 1 |
| Akutsu, M; Furukawa, Y; Honma, Y; Kano, Y; Mano, H; Sato, Y; Tsunoda, S | 1 |
| Elefanty, A; Layton, JE; Lieschke, GJ; Sun, X | 1 |
| Rutherford, A | 1 |
| Bhalla, KN; Nguyen, D; Nimmanapalli, R; Perkins, C; Porosnicu, M; Worthington, E | 1 |
| Baron, F; Beguin, Y; Fillet, G; Frère, P | 1 |
| Heinzl, S | 1 |
| Countouriotis, A; Moore, TB; Sakamoto, KM | 1 |
| Nara, N | 1 |
| Gambacorti-Passerini, C | 1 |
| Bär, C; Debatin, KM; Hecker, S; Reinhardt, D; Schmidt-Rohr, U; Selle, B; Viehmann, S | 1 |
32 review(s) available for imatinib mesylate and Leucocythaemia
| Article | Year |
|---|---|
Clinical Profile and Treatment in Hypereosinophilic Syndrome Variants: A Pragmatic Review.
Topics: Adrenal Cortex Hormones; Eosinophils; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Male | 2022 |
PDGF receptor signaling networks in normal and cancer cells.
Topics: Benzamides; Fibrosis; Gastrointestinal Stromal Tumors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Infections; Leukemia; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Stroke | 2014 |
Eosinophilia in Hematologic Disorders.
Topics: Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Leukemia, Myelomonocytic, Chronic; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta | 2015 |
Management of Hypereosinophilic Syndromes.
Topics: Adrenal Cortex Hormones; Eosinophils; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Interferon-alpha; Leukemia; mRNA Cleavage and Polyadenylation Factors; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor alpha | 2015 |
[Treatment of adult acute lymphoblastie leukemia with eosinophilia and abnormality of PDGFRA by autologous hematopoietic stem cell transplantation and imatinib: one case report and literatures review].
Topics: Adult; Eosinophilia; Hematopoietic Stem Cell Transplantation; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptor, Platelet-Derived Growth Factor alpha | 2015 |
[Literature review and presentation of our own research results regarding the effects on bone of tyrosine kinase inhibitors imatinib and nilotinib used in the treatment of oncohematological diseases].
Topics: Antineoplastic Agents; Bone and Bones; Cell Survival; Imatinib Mesylate; Leukemia; Osteoclasts; Pyrimidines | 2016 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
Graft-versus-leukemia effects of transplantation and donor lymphocytes.
Topics: Antineoplastic Agents; Benzamides; Blood Donors; Graft vs Host Disease; Graft vs Host Reaction; Graft vs Leukemia Effect; Humans; Imatinib Mesylate; Immune Tolerance; Immunotherapy, Adoptive; Leukemia; Lymphocyte Transfusion; Lymphocytes; Piperazines; Pyrimidines; Transplantation Immunology; Tumor Escape | 2008 |
AHI-1: a novel signaling protein and potential therapeutic target in human leukemia and brain disorders.
Topics: Adaptor Proteins, Signal Transducing; Adaptor Proteins, Vesicular Transport; Animals; Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia; Lymphoma; Mice; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Piperazines; Pyrimidines | 2011 |
[Leukemia: A highly malignant disease].
Topics: Animals; Antineoplastic Agents; Benzamides; Dasatinib; Disease Models, Animal; History, 19th Century; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines; Thiazoles; Tretinoin | 2012 |
Targeted therapies for the treatment of leukemia.
Topics: Alemtuzumab; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Dose-Response Relationship, Drug; Drug Interactions; Gemtuzumab; Humans; Imatinib Mesylate; Leukemia; Nurse-Patient Relations; Nurse's Role; Oncology Nursing; Oxides; Patient Education as Topic; Piperazines; Prognosis; Pyrimidines; Randomized Controlled Trials as Topic; Tretinoin | 2003 |
Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.
Topics: Animals; Benzamides; Binding Sites; Clinical Trials as Topic; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myeloid; Mice; Mutation; Piperazines; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrimidines; Receptor Protein-Tyrosine Kinases; Signal Transduction; src Homology Domains | 2003 |
Targeting PDGF receptors in cancer--rationales and proof of concept clinical trials.
Topics: Benzamides; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia; Ligands; Male; Models, Biological; Mutation; Neoplasms; Neovascularization, Pathologic; Piperazines; Platelet-Derived Growth Factor; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Platelet-Derived Growth Factor | 2003 |
Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.
Topics: Animals; Benzamides; Eosinophilia; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Substrate Specificity | 2004 |
Innovations in the management of leukemia: role of biologic therapies.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Combined Modality Therapy; Humans; Imatinib Mesylate; Leukemia; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2003 |
Molecular mechanisms of resistance of leukemia to imatinib mesylate.
Topics: Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genetic Heterogeneity; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines | 2004 |
[Tyrosine kinase inhibitor STI571--a breakthrough in leukemia treatment?].
Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2003 |
Imatinib mesylate selectively influences the cellular metabolism of cytarabine in BCR/ABL negative leukemia cell lines and normal CD34+ progenitor cells.
Topics: Antigens, CD; Antigens, CD34; Benzamides; Bone Marrow Cells; Cell Line, Tumor; Cytarabine; Gene Deletion; Genes, abl; Humans; Imatinib Mesylate; Leukemia; Piperazines; Pyrimidines | 2004 |
Plasma cell myeloma and leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Child; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia; Multiple Myeloma; Piperazines; Pyrimidines | 2003 |
[Inhibition of relapse in leukemia by using molecular targeting therapy].
Topics: Benzamides; Drug Delivery Systems; Humans; Imatinib Mesylate; Leukemia; Piperazines; Pyrimidines; Tretinoin | 2004 |
[Current progress in therapy of malignant diseases].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia; Lymphoma; Neoplasms; Piperazines; Pyrimidines | 2005 |
Mitochondria-dependent apoptosis in T-cell homeostasis.
Topics: Animals; Antiviral Agents; Apoptosis; Autoimmune Diseases; Benzamides; Clonal Deletion; HIV Infections; Homeostasis; Humans; Imatinib Mesylate; Immunotherapy, Active; Leukemia; Lymphocyte Activation; Mitochondria; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; T-Lymphocytes; Thymus Gland | 2005 |
[Targeting Ras related proteins for leukemia therapy].
Topics: Animals; Antineoplastic Agents; Benzamides; Diphosphonates; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; ras Proteins; Signal Transduction | 2005 |
[Molecular targeting therapy of hematopoietic tumors].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Drug Delivery Systems; Humans; Imatinib Mesylate; Leukemia; Lymphoma; Piperazines; Pyrimidines; Rituximab | 2006 |
Disease relapse after haematopoietic stem cell transplantation: risk factors and treatment.
Topics: Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Transfusion; Piperazines; Pyrimidines; Risk Factors; Secondary Prevention; Transplantation, Homologous | 2007 |
[Recent advances on molecular targets for treatment of acute leukemia].
Topics: Acute Disease; Antineoplastic Agents; Benzamides; Cell Proliferation; Humans; Imatinib Mesylate; Leukemia; Piperazines; Pyrimidines; Transcription Factors | 2007 |
FLT3 as a therapeutic target in childhood acute leukemia.
Topics: Acute Disease; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Drug Delivery Systems; fms-Like Tyrosine Kinase 3; Gene Expression Regulation; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia; Mice; Mutation; Piperazines; Pyrimidines | 2007 |
Leukemia, an effective model for chemical biology and target therapy.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Dasatinib; Growth Inhibitors; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Oxides; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Tretinoin | 2007 |
From dissection of disease pathogenesis to elucidation of mechanisms of targeted therapies: leukemia research in the genomic era.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Disease Models, Animal; Humans; Imatinib Mesylate; Leukemia; Oxides; Piperazines; Pyrimidines; Tretinoin | 2007 |
[Molecular physiopathology and molecular targeting therapy of leukemia].
Topics: Benzamides; Benzoates; Humans; Imatinib Mesylate; Leukemia; Piperazines; Pyrimidines; Tetrahydronaphthalenes | 2007 |
Cell surface antigen and molecular targeting in the treatment of hematologic malignancies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antigens, Surface; Antineoplastic Agents; Benzamides; Hematologic Diseases; Humans; Imatinib Mesylate; Leukemia; Leukocyte Common Antigens; Lymphoma, B-Cell; Piperazines; Pyrimidines; Rituximab; Sialic Acid Binding Ig-like Lectin 3 | 2002 |
[Molecular diagnosis in hematologic malignancies].
Topics: Antineoplastic Agents; Benzamides; Gene Expression Regulation, Leukemic; Gene Targeting; Genetic Therapy; Humans; Imatinib Mesylate; Leukemia; Molecular Diagnostic Techniques; Neoplasm, Residual; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Tretinoin | 2002 |
5 trial(s) available for imatinib mesylate and Leucocythaemia
| Article | Year |
|---|---|
Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study.
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia; Nitriles; Philadelphia Chromosome; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors | 2023 |
Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Drug Administration Schedule; Fasciitis; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Joints; Leukemia; Male; Middle Aged; Mycophenolic Acid; Pilot Projects; Prednisone; Range of Motion, Articular; Recurrence; Skin Diseases; Tacrolimus; Transplantation, Homologous | 2015 |
Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclin-Dependent Kinases; Female; Flavonoids; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia; Male; Middle Aged; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2012 |
Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study.
Topics: Adolescent; Adult; Benzamides; Child; Child, Preschool; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Infant; Leukemia; Pharmacokinetics; Philadelphia Chromosome; Piperazines; Pyrimidines; Salvage Therapy; Survival Analysis; Treatment Outcome | 2004 |
Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Haplotypes; Histocompatibility; HLA Antigens; Humans; Imatinib Mesylate; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia; Lymphocyte Transfusion; Male; Methotrexate; Mitoxantrone; Pancytopenia; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Recurrence; Remission Induction; Salvage Therapy; Tissue Donors; Treatment Outcome | 2007 |
135 other study(ies) available for imatinib mesylate and Leucocythaemia
| Article | Year |
|---|---|
[The Effect of hnRNPK/Beclin1 Signaling on the Drug Resistance of Imatinib in Ph
Topics: Antineoplastic Agents; Beclin-1; Cell Line, Tumor; Drug Resistance; Drug Resistance, Neoplasm; Heterogeneous-Nuclear Ribonucleoprotein K; Humans; Imatinib Mesylate; Leukemia | 2022 |
Synthesis and Anti-Cancer Activity of New Pyrazolinyl-Indole Derivatives: Pharmacophoric Interactions and Docking Studies for Identifying New EGFR Inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Humans; Imatinib Mesylate; Indoles; Leukemia; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Structure-Activity Relationship | 2022 |
An integrated microfluidics platform with high-throughput single-cell cloning array and concentration gradient generator for efficient cancer drug effect screening.
Topics: Clone Cells; Cloning, Molecular; Early Detection of Cancer; Humans; Imatinib Mesylate; Leukemia; Microfluidics; Resveratrol | 2022 |
[FIP1L1::PDGFRA-positive chronic eosinophilic leukemia presenting with multiple ulcers of oral cavity and gastrointestinal tract].
Topics: Humans; Imatinib Mesylate; Leukemia; Mouth | 2022 |
Successful treatment with imatinib of lymphomatoid papulosis associated with myeloproliferative hypereosinophilic syndrome with PDGFRA rearrangement.
Topics: Antineoplastic Agents; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Lymphomatoid Papulosis; Male; Middle Aged; Protein Kinase Inhibitors; Skin Neoplasms; Treatment Outcome | 2020 |
A novel NAP1L4/NUTM1 fusion arising from translocation t(11;15)(p15;q12) in a myeloid neoplasm with eosinophilia and rearrangement of PDGFRA highlights an unusual clinical feature and therapeutic reaction.
Topics: Adult; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 15; Eosinophilia; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Male; Mutation; Myeloproliferative Disorders; Neoplasm Proteins; Nuclear Proteins; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Translocation, Genetic | 2020 |
Genomic analysis of mutations in platelet mitochondria in a case of benzene-induced leukaemia: A case report.
Topics: Antineoplastic Agents; Benzene; Blood Platelets; Environmental Exposure; Female; Genome, Mitochondrial; Humans; Imatinib Mesylate; Leukemia; Middle Aged; Mitochondria | 2021 |
High-throughput liquid chromatography/electrospray ionization-tandem mass spectrometry method using in-source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma.
Topics: Adenine; Aniline Compounds; Chromatography, Liquid; Dasatinib; Drug Monitoring; Female; High-Throughput Screening Assays; Humans; Imatinib Mesylate; Leukemia; Male; Middle Aged; Nitriles; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2021 |
An activating mutation of GNB1 is associated with resistance to tyrosine kinase inhibitors in ETV6-ABL1-positive leukemia.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; GTP-Binding Protein beta Subunits; Humans; Imatinib Mesylate; Leukemia; Mutation; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction | 2017 |
Loeffler endocarditis in chronic eosinophilic leukemia with FIP1L1/PDGFRA rearrangement: full recovery with low dose imatinib.
Topics: Adult; Gene Rearrangement; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor alpha; Republic of Korea | 2018 |
[Anti-Leukemia Effect and Mechanism of Oridonin on Imatinib-Sensitive and Imatinib-Resistant K562 Cells].
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Diterpenes, Kaurane; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia; Piperazines; Pyrimidines | 2017 |
A novel fusion of PDGFRB to TSC1, an intrinsic suppressor of mTOR-signaling pathway, in a chronic eosinophilic leukemia patient with t(5;9)(q32;q34).
Topics: Blood Cell Count; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 9; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Male; Middle Aged; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; TOR Serine-Threonine Kinases; Translocation, Genetic; Treatment Outcome; Tuberous Sclerosis Complex 1 Protein | 2018 |
Alginate foam-based three-dimensional culture to investigate drug sensitivity in primary leukaemia cells.
Topics: Alginates; Cell Culture Techniques; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia; Tumor Microenvironment | 2018 |
[Targeted sequencing analysis of hyper-eosinophilic syndrome and chronic eosinophilic leukemia].
Topics: Chronic Disease; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta | 2018 |
[Clinical Characteristics and Prognosis of patients with Variant Philadelphia Chromosome Positive Leukemia].
Topics: Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia; Philadelphia Chromosome; Prognosis | 2018 |
Imatinib stimulates prostaglandin E
Topics: Abelson murine leukemia virus; Cytokines; Dinoprostone; Humans; Imatinib Mesylate; Inflammation; Leukemia; Lipopolysaccharides; Monocytes; NF-kappa B; Philadelphia Chromosome; Platelet Activation; Proto-Oncogene Proteins c-bcr; Receptors, Prostaglandin E, EP4 Subtype; Signal Transduction; Th1-Th2 Balance; Thromboxane A2; U937 Cells | 2019 |
Polyarthritis as the Initial Presentation of Hyper Eosinophilic Syndrome.
Topics: Aged; Anti-Bacterial Agents; Arthritis; Arthritis, Infectious; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Prednisolone; Treatment Outcome | 2019 |
Functional genomics to identify unforeseen cancer drug targets.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Benzamides; Breast Neoplasms; Casein Kinase I; Cell Cycle Proteins; DNA-Binding Proteins; Female; Genes, myc; Genes, ras; Genomics; Humans; Imatinib Mesylate; Leukemia; Mice; Molecular Targeted Therapy; Mutation; Piperazines; Protein Serine-Threonine Kinases; Pyrimidines; Receptor, ErbB-2; RNA Interference; Trastuzumab; Tumor Suppressor Proteins | 2013 |
Leukaemia.
Topics: Benzamides; Child; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines | 2013 |
Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia.
Topics: Benzamides; Cell Line; Cell Survival; Chromatography, Affinity; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoblotting; Leukemia; NF-kappa B; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; src-Family Kinases; Thiazoles | 2013 |
Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells.
Topics: Benzamides; Boronic Acids; Bortezomib; Caspases; Cell Death; Cell Line, Tumor; Dasatinib; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Fusion Proteins, bcr-abl; Heterocyclic Compounds, 2-Ring; Humans; Imatinib Mesylate; JNK Mitogen-Activated Protein Kinases; Leukemia; Mitosis; Models, Biological; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pteridines; Pyrazines; Pyrimidines; Signal Transduction; STAT5 Transcription Factor; Thiazoles | 2013 |
Synergistic anti-leukemic activity of imatinib in combination with a small molecule Grb2 SH2 domain binding antagonist.
Topics: Aldehyde Dehydrogenase; Antineoplastic Agents; Benzamides; Drug Synergism; GRB2 Adaptor Protein; Humans; Imatinib Mesylate; K562 Cells; Leukemia; MicroRNAs; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src Homology Domains | 2014 |
RNA-seq identifies clinically relevant fusion genes in leukemia including a novel MEF2D/CSF1R fusion responsive to imatinib.
Topics: Antineoplastic Agents; Benzamides; Gene Fusion; Humans; Imatinib Mesylate; Leukemia; MEF2 Transcription Factors; Piperazines; Pyrimidines; Receptor, Macrophage Colony-Stimulating Factor; Receptor, Platelet-Derived Growth Factor beta; Sequence Analysis, RNA | 2014 |
Successful treatment with imatinib in a patient with chronic eosinophilic leukemia not otherwise specified.
Topics: Antineoplastic Agents; Benzamides; Dyspnea; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Male; Middle Aged; Muscle Weakness; Piperazines; Pyrimidines; Sweating | 2014 |
Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms.
Topics: Adult; Amino Acid Sequence; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 5; Chronic Disease; DNA-Binding Proteins; Eosinophilia; Gene Fusion; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Leukemia; Male; Microfilament Proteins; Molecular Sequence Data; Myeloproliferative Disorders; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Remission Induction; Translocation, Genetic | 2014 |
Imatinib non-responsive chronic eosinophilic leukemia with ETV6-PDGFRA fusion gene.
Topics: Antineoplastic Agents; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 4; Drug Resistance, Neoplasm; ETS Translocation Variant 6 Protein; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotype; Leukemia; Male; Middle Aged; Oncogene Proteins, Fusion; Proto-Oncogene Proteins c-ets; Receptor, Platelet-Derived Growth Factor alpha; Repressor Proteins; Translocation, Genetic | 2015 |
Identification of kit(M541L) somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response.
Topics: Adolescent; Aged; Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Karyotype; Leukemia; Male; Middle Aged; Mutation, Missense; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Retrospective Studies; Time Factors; Treatment Outcome | 2014 |
[Sustained hematologic response in chronic eosinophilic leukemia with low dose imatinib. Report of one case].
Topics: Antineoplastic Agents; Benzamides; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome | 2014 |
Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzamides; Cell Growth Processes; Drug Resistance; Gene Expression Regulation, Neoplastic; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; mRNA Cleavage and Polyadenylation Factors; Mutation; Oncogene Protein v-akt; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2014 |
Stromal cells attenuate the cytotoxicity of imatinib on Philadelphia chromosome-positive leukemia cells by up-regulating the VE-cadherin/β-catenin signal.
Topics: Antigens, CD; Antineoplastic Agents; Benzamides; beta Catenin; Cadherins; Cell Line, Tumor; Coculture Techniques; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia; Neoplasm Proteins; Philadelphia Chromosome; Piperazines; Pyrimidines; Signal Transduction; Stromal Cells; Up-Regulation | 2014 |
Comprehensive genomic profiling identifies a novel TNKS2-PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy.
Topics: Benzamides; Eosinophilia; Female; Genome, Human; High-Throughput Nucleotide Sequencing; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Middle Aged; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Tankyrases | 2015 |
[Clinical efficacy of switching to 2nd generation of tyrosine kinase inhibitor on CML patients at poor responses to imatinib].
Topics: Benzamides; Blast Crisis; Cytogenetics; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Treatment Outcome | 2015 |
A rapid and high content assay that measures cyto-ID-stained autophagic compartments and estimates autophagy flux with potential clinical applications.
Topics: Animals; Autophagy; Cell Survival; Chloroquine; Dactinomycin; Endosomes; Fluorescent Dyes; Gene Expression Regulation, Leukemic; HEK293 Cells; HeLa Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia; Lysosomes; MAP Kinase Kinase Kinases; Mice; Mice, Inbred C57BL; Mice, SCID; Microscopy, Fluorescence; Neoplasm Transplantation; Protein Serine-Threonine Kinases; RNA Interference; Spectrometry, Fluorescence | 2015 |
Generalized Eruptive Histiocytosis Associated With FIP1L1-PDGFRA-Positive Chronic Eosinophilic Leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Histiocytosis, Non-Langerhans-Cell; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2015 |
A novel FOXP1-PDGFRA fusion gene in myeloproliferative neoplasm with eosinophilia.
Topics: Adult; Antineoplastic Agents; Cytogenetic Analysis; Forkhead Transcription Factors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Male; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor alpha; Repressor Proteins | 2015 |
Successful Heart Transplantation for Unreversible Endomyocardial Fibrosis Related to FIP1L1-PDGFRA Chronic Eosinophilic Leukemia.
Topics: Adult; Antineoplastic Agents; Biopsy; Cardiomyopathies; Fibrosis; Heart Transplantation; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Magnetic Resonance Imaging; Male; mRNA Cleavage and Polyadenylation Factors; Myocardium; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome | 2015 |
Oral mucosal manifestations of chronic eosinophilic leukaemia with FIP1L1-PDGFRα.
Topics: Antineoplastic Agents; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Oral Ulcer; Receptor, Platelet-Derived Growth Factor alpha | 2016 |
"Imatinib-induced gastric antral vascular ectasia" in a reporting system of the Japanese Adverse Drug Event Report database.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Female; Gastric Antral Vascular Ectasia; Humans; Imatinib Mesylate; Japan; Leukemia; Male; Middle Aged | 2016 |
Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; China; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gene Fusion; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia; Maintenance Chemotherapy; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Mutation; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Time Factors; Treatment Outcome; Young Adult | 2016 |
Severe Prolonged Cough as Presenting Manifestation of FIP1L1-PDGFRA+ Chronic Eosinophilic Leukaemia: A Widely Ignored Association.
Topics: Aged; Antineoplastic Agents; Chronic Disease; Cough; Delayed Diagnosis; Diagnosis, Differential; DNA-Binding Proteins; Gene Fusion; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia; Lung; Male; mRNA Cleavage and Polyadenylation Factors; Real-Time Polymerase Chain Reaction; Receptor, Platelet-Derived Growth Factor alpha; Tomography, X-Ray Computed; Transcription Factors | 2016 |
Fibroblast Growth Factor-2 facilitates the growth and chemo-resistance of leukemia cells in the bone marrow by modulating osteoblast functions.
Topics: Animals; Antineoplastic Agents; Bone Marrow Cells; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cytarabine; Drug Resistance, Neoplasm; Fibroblast Growth Factor 2; Humans; Imatinib Mesylate; Leukemia; Mice; Neoplasm Transplantation; Osteoblasts; Tumor Microenvironment | 2016 |
Response: Co-administration of cyclosporine A and imatinib among patients with Philadelphia chromosome-positive leukemias in the post-transplant setting.
Topics: Antineoplastic Agents; Benzamides; Cyclosporine; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines | 2016 |
Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells.
Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; Benzamides; Cell Transformation, Neoplastic; Cells, Cultured; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia; Lymphocytes; Mice; Mice, Inbred BALB C; Myeloid Cells; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2008 |
Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Cell Transformation, Neoplastic; Gene Expression; HL-60 Cells; Humans; Imatinib Mesylate; Inhibitor of Differentiation Protein 1; K562 Cells; Leukemia; Leukemia, Experimental; Mice; Oncogenes; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; RNA, Small Interfering; Signal Transduction | 2008 |
Inhibition of apoptosome formation by suppression of Hsp90beta phosphorylation in tyrosine kinase-induced leukemias.
Topics: Animals; Apoptosomes; Apoptotic Protease-Activating Factor 1; Benzamides; Bone Marrow Cells; Caspase 9; Cell Line; Cytochromes c; Drug Resistance, Neoplasm; Enzyme Induction; Fusion Proteins, bcr-abl; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Leukemia; Mice; Mutant Proteins; Phosphorylation; Phosphoserine; Piperazines; Protein Binding; Protein-Tyrosine Kinases; Pyrimidines | 2008 |
XXIII International Association for Comparative Research on Leukemia and Related Diseases Symposium: from molecular pathogenesis to targeted therapy in leukemia and solid tumors.
Topics: Adolescent; Adult; Age Factors; Aged; Animals; Benzamides; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myeloid, Acute; Medical Oncology; Mice; Middle Aged; Myelodysplastic Syndromes; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Transcription Factors | 2008 |
The key role of stem cell factor/KIT signaling in the proliferation of blast cells from Down syndrome-related leukemia.
Topics: Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Down Syndrome; Female; GATA1 Transcription Factor; Humans; Imatinib Mesylate; Infant; Infant, Newborn; Leukemia; Male; Mutation; Piperazines; Pyrimidines; Signal Transduction; Stem Cell Factor | 2009 |
[Hematological disorders and hypereosinophilias].
Topics: Antineoplastic Agents; Benzamides; Eosinophilia; Gene Rearrangement; Glucocorticoids; Hematologic Diseases; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Piperazines; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta | 2009 |
Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Cell Proliferation; Chromatography, High Pressure Liquid; Fatty Acids; Fusion Proteins, bcr-abl; Glucose; Humans; Imatinib Mesylate; K562 Cells; Kinetics; Lactic Acid; Leukemia; Magnetic Resonance Spectroscopy; Phospholipids; Phosphorylation; Piperazines; Pyrimidines; Time Factors | 2009 |
Berbamine derivatives: a novel class of compounds for anti-leukemia activity.
Topics: Animals; Antineoplastic Agents; Benzamides; Benzylisoquinolines; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia; Piperazines; Pyrimidines | 2009 |
Growth factor independent 1b (Gfi1b) and a new splice variant of Gfi1b are highly expressed in patients with acute and chronic leukemia.
Topics: Acute Disease; Alternative Splicing; Animals; Antineoplastic Agents; Benzamides; Chlorocebus aethiops; Chronic Disease; COS Cells; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Pyrimidines; RNA, Messenger; Transcription Factors; Zinc Finger Protein GLI1 | 2009 |
High-resolution melting analysis for a reliable and two-step scanning of mutations in the tyrosine kinase domain of the chimerical bcr-abl gene.
Topics: Benzamides; DNA Mutational Analysis; Female; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Jurkat Cells; K562 Cells; Leukemia; Male; Mutation; Philadelphia Chromosome; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; U937 Cells | 2009 |
Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Drug Resistance, Neoplasm; Female; Forkhead Transcription Factors; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia; Mice; Mice, Nude; Piperazines; Proteasome Inhibitors; Pyrazines; Pyrimidines; Remission Induction; Tumor Cells, Cultured; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2009 |
Reproductive fitness advantage of BCR-ABL expressing leukemia cells.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Differentiation; Cell Division; Cell Movement; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Genetic Fitness; Hematopoiesis; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Genetic; Mutation; Oncogenes; Phenotype; Piperazines; Probability; Pyrimidines | 2010 |
Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia; Mice; Mutation; Piperazines; Pyrimidines; RNA, Small Interfering | 2010 |
Honokiol induces paraptosis and apoptosis and exhibits schedule-dependent synergy in combination with imatinib in human leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Biphenyl Compounds; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Drug Administration Schedule; Drug Synergism; Humans; Imatinib Mesylate; Leukemia; Lignans; Piperazines; Pyrimidines; Vacuoles | 2010 |
Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.
Topics: Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Cell Separation; Cell Transformation, Neoplastic; Female; Flow Cytometry; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Male; Mice; Piperazines; Point Mutation; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Reverse Transcriptase Polymerase Chain Reaction; Xenograft Model Antitumor Assays | 2011 |
[Acute leukemia of ambiguous lineage with monosomy 7 and Philadelphia chromosome].
Topics: Acute Disease; Aged; Antineoplastic Agents; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 7; Diagnosis, Differential; Fatal Outcome; Female; Heart Failure; Humans; Imatinib Mesylate; Leukemia; Philadelphia Chromosome; Piperazines; Pyrimidines | 2011 |
Endoplasmic reticulum stress inducers, but not imatinib, sensitize Philadelphia chromosome-positive leukemia cells to TRAIL-mediated apoptosis.
Topics: Antineoplastic Agents; Antiviral Agents; Apoptosis; Benzamides; Blotting, Western; Endoplasmic Reticulum; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia; Philadelphia Chromosome; Piperazines; Pyrimidines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thapsigargin; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tunicamycin | 2011 |
Pro-apoptotic activity of α-bisabolol in preclinical models of primary human acute leukemia cells.
Topics: Adolescent; Adult; Apoptosis; Benzamides; BH3 Interacting Domain Death Agonist Protein; Blast Crisis; Blood Cells; Cell Respiration; Cluster Analysis; Culture Media; Drug Screening Assays, Antitumor; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia; Male; Membrane Potential, Mitochondrial; Middle Aged; Mitochondria; Models, Biological; Monocyclic Sesquiterpenes; Mutation; Piperazines; Pyrimidines; Sesquiterpenes; Solubility; Time Factors; Tumor Cells, Cultured; Young Adult | 2011 |
In vitro synergism between LFA-1 targeting leukotoxin (Leukothera™) and standard chemotherapeutic agents in leukemia cells.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Busulfan; Cell Line, Tumor; Daunorubicin; Drug Interactions; Drug Synergism; Etoposide; Exotoxins; Flow Cytometry; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia; Leukocytes; Lymphocyte Function-Associated Antigen-1; Membrane Potential, Mitochondrial; Mitoxantrone; Piperazines; Pyrimidines; Tumor Cells, Cultured | 2011 |
Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells.
Topics: Animals; Arsenic Trioxide; Arsenicals; Benzamides; Cell Death; Cell Line, Tumor; Cell Respiration; Drug Resistance, Neoplasm; Electron Transport; Energy Metabolism; Glucose; Imatinib Mesylate; Isothiocyanates; Leukemia; Mice; Mitochondria; Models, Biological; Oxidative Stress; Oxides; Piperazines; Pyrimidines; Reactive Oxygen Species | 2011 |
The in-vitro antiproliferative effect of PRI-2191 and imatinib applied in combined treatment with cisplatin, idarubicin, or docetaxel on human leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Cycle Checkpoints; Cell Proliferation; Cisplatin; Dihydroxycholecalciferols; Docetaxel; G1 Phase Cell Cycle Checkpoints; HL-60 Cells; Humans; Idarubicin; Imatinib Mesylate; K562 Cells; Leukemia; Piperazines; Pyrimidines; Taxoids | 2012 |
Optical, structural and thermodynamic studies of the association of an anti-leucamic drug imatinib mesylate with transport protein.
Topics: Absorption; Antineoplastic Agents; Benzamides; Energy Transfer; Humans; Imatinib Mesylate; Leukemia; Metals; Optical Phenomena; Piperazines; Protein Binding; Pyrimidines; Serum Albumin; Spectrum Analysis; Thermodynamics | 2012 |
Tyrosine kinase chromosomal translocations mediate distinct and overlapping gene regulation events.
Topics: Benzamides; Cell Line, Tumor; Enzyme Activation; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia; Oligonucleotide Array Sequence Analysis; Oncogene Proteins, Fusion; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; RNA, Messenger; Translocation, Genetic | 2011 |
Sulforaphane potentiates the efficacy of imatinib against chronic leukemia cancer stem cells through enhanced abrogation of Wnt/β-catenin function.
Topics: ADP-ribosyl Cyclase 1; Anticarcinogenic Agents; Antigens, CD34; Antineoplastic Agents; Apoptosis; Benzamides; beta Catenin; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation; Glutathione; Glutathione S-Transferase pi; Humans; Imatinib Mesylate; Isothiocyanates; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Pyrimidines; Sulfoxides; Thiocyanates; Wnt Signaling Pathway | 2012 |
Combined treatment of 3-hydroxyflavone and imatinib mesylate increases apoptotic cell death of imatinib mesylate-resistant leukemia cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Death; Cell Survival; Cells, Cultured; Dogs; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Flavonoids; Humans; Imatinib Mesylate; K562 Cells; Leukemia; Piperazines; Pyrimidines | 2012 |
Effect of plasma membrane cholesterol depletion on glucose transport regulation in leukemia cells.
Topics: Benzamides; beta-Cyclodextrins; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Cell Survival; Cholesterol; Cytoplasmic Vesicles; Endocytosis; Extracellular Signal-Regulated MAP Kinases; Glucose; Glucose Transporter Type 1; Humans; Imatinib Mesylate; Leukemia; Nystatin; Phloretin; Phospholipase C gamma; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein Transport; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; Stem Cell Factor | 2012 |
Diverse underlying proliferation response to growth factors in imatinib-treated Philadelphia chromosome-positive leukemias.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Imatinib Mesylate; Intercellular Signaling Peptides and Proteins; Interleukin-6; Leukemia; Philadelphia Chromosome; Piperazines; Pyrimidines | 2013 |
Imatinib mesylate and nilotinib affect MHC-class I presentation by modulating the proteasomal processing of antigenic peptides.
Topics: Amino Acid Sequence; Antigen Presentation; Antigens, Neoplasm; Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Histocompatibility Antigens Class I; HLA-A Antigens; HLA-B Antigens; Humans; Imatinib Mesylate; K562 Cells; Leukemia; Molecular Sequence Data; Peptide Fragments; Piperazines; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Protein Phosphatase 2; Pyrimidines | 2013 |
PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
Topics: Animals; Antigens, CD34; Benzamides; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Gene Knockdown Techniques; Hematopoietic Stem Cells; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Imatinib Mesylate; K562 Cells; Leukemia; Mice; Piperazines; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyrimidines; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2013 |
Engineering a BCR-ABL-activated caspase for the selective elimination of leukemic cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Caspase 8; Caspases; Drug Resistance, Neoplasm; Enzyme Activation; Fusion Proteins, bcr-abl; Genetic Variation; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia; Mice; Piperazines; Protein Engineering; Protein Kinase Inhibitors; Pyrimidines; Recombinant Proteins; Transduction, Genetic | 2013 |
Imatinib-induced amelioration of neurologic deficits in a rare case of simultaneous association of missed multiple sclerosis and chronic myeloblastic leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Brain; Chronic Disease; Humans; Imatinib Mesylate; Leukemia; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Piperazines; Pyrimidines | 2013 |
Acquired resistance to imatinib mesylate: selection for pre-existing mutant cells.
Topics: Antineoplastic Agents; Benzamides; Clone Cells; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia; Piperazines; Pyrimidines | 2002 |
Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi).
Topics: Apoptosis; Benzamides; Gene Silencing; Genes, abl; Genetic Therapy; Humans; Imatinib Mesylate; K562 Cells; Leukemia; Piperazines; Pyrimidines; RNA, Double-Stranded; RNA, Messenger | 2002 |
Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases.
Topics: Apoptosis; Benzamides; Binding Sites; Cell Division; Cell Survival; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia; Models, Molecular; Mutagenesis, Site-Directed; Oncogene Proteins v-abl; Piperazines; Protein Conformation; Pyrazoles; Pyrimidines; Pyrroles; src-Family Kinases | 2003 |
Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Benzamides; Cell Division; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Telomerase; Telomere; Time Factors | 2002 |
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Cell Death; Cell Division; Colony-Forming Units Assay; Cyclosporins; Doxorubicin; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression; Genes, MDR; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphotyrosine; Piperazines; Pyrimidines; Transfection; Tumor Cells, Cultured; Verapamil | 2003 |
Cancer: Escape from inhibition.
Topics: Benzamides; Crystallography, X-Ray; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Leukemia; Oncogene Proteins v-abl; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines; src Homology Domains | 2003 |
Fighting leukemia. Survival rates have tripled thanks to new, more effective treatments.
Topics: Acute Disease; Age Factors; Antineoplastic Agents; Benzamides; Chronic Disease; Cladribine; Humans; Imatinib Mesylate; Leukemia; Piperazines; Pyrimidines; Survival Rate | 2003 |
Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571.
Topics: Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Cell Line; Cell Line, Transformed; Cell Transformation, Neoplastic; COS Cells; DNA, Complementary; Fibroblasts; Fusion Proteins, bcr-abl; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia; Mice; Microscopy, Fluorescence; Mutation; Oncogene Proteins; Phosphorylation; Piperazines; Protein Binding; Protein Conformation; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcr; Pyrimidines; Rats; Recombinant Fusion Proteins; Retroviridae; Time Factors | 2003 |
Imatinib: resisting the resistance.
Topics: Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2003 |
[New trends in therapy for leukemia: Approach from the point of view of molecular information].
Topics: Benzamides; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Targeting; Humans; Imatinib Mesylate; Leukemia; Molecular Diagnostic Techniques; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic | 2003 |
[Glivec in combination with HA regimen for treatment of 20 patients with Ph chromosome positive acute leukemia].
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Follow-Up Studies; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines | 2003 |
Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Central Nervous System Neoplasms; Chromatography, High Pressure Liquid; Clinical Trials as Topic; DNA Mutational Analysis; Female; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Metastasis; Phenotype; Piperazines; Prognosis; Pyrimidines; Risk; Risk Factors; Time Factors; Treatment Outcome | 2003 |
Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft.
Topics: Adult; Benzamides; Cord Blood Stem Cell Transplantation; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Male; Molecular Diagnostic Techniques; Piperazines; Polymerase Chain Reaction; Pyrimidines; Recurrence; Remission Induction; Transplantation, Homologous | 2004 |
[The reverse effect on drug-resistance against tyrosine kinase inhibitor STI571 in mdr1 and bcr-abl positive leukemic cells].
Topics: Antineoplastic Agents; Benzamides; Cyclosporine; Drug Resistance, Neoplasm; Genes, abl; Genes, MDR; Humans; Imatinib Mesylate; Interferon-alpha; K562 Cells; Leukemia; Piperazines; Pyrimidines; Tamoxifen | 2003 |
Establishment and phenotypic characterization of human U937 cells with inducible P210 BCR/ABL expression reveals upregulation of CEACAM1 (CD66a).
Topics: Antigens, CD; Antigens, Differentiation; Antineoplastic Agents; Apoptosis; Benzamides; Carcinoembryonic Antigen; Cell Adhesion Molecules; Cell Cycle; Cell Differentiation; DNA-Binding Proteins; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia; Milk Proteins; Phenotype; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; STAT1 Transcription Factor; STAT3 Transcription Factor; STAT5 Transcription Factor; Trans-Activators; Transfection; U937 Cells; Up-Regulation | 2004 |
Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Benzamides; Cell Division; Cell Line, Tumor; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Sirolimus; Staurosporine | 2004 |
Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines.
Topics: Antineoplastic Agents; Benzamides; Cell Death; Cell Division; Cell Line, Tumor; Cytarabine; Daunorubicin; Diphosphonates; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Hydroxyurea; Imatinib Mesylate; Imidazoles; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Piperazines; Pyrimidines; Vincristine; Zoledronic Acid | 2004 |
Gene expression signatures in lymphoid tumours.
Topics: Antineoplastic Agents; Benzamides; Gene Expression; Gene Expression Profiling; Humans; Imatinib Mesylate; Leukemia; Lymphoma; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Piperazines; Pyrimidines; RNA, Messenger | 2004 |
The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase.
Topics: Animals; Antineoplastic Agents; Benzamides; Chlorocebus aethiops; COS Cells; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Glutamic Acid; Humans; Imatinib Mesylate; Leukemia; Milk Proteins; Mutation; Phosphorylation; Piperazines; Protein Structure, Tertiary; Pyrimidines; STAT5 Transcription Factor; Threonine; Trans-Activators | 2004 |
Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner.
Topics: Adaptor Proteins, Signal Transducing; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Benzamides; CD8-Positive T-Lymphocytes; Cell Proliferation; Clinical Trials as Topic; Cytomegalovirus; Dose-Response Relationship, Drug; Genome, Human; Graft vs Host Disease; Graft vs Leukemia Effect; Herpesvirus 4, Human; Humans; Imatinib Mesylate; Immunodominant Epitopes; Interleukin-2; Jurkat Cells; Lectins, C-Type; Leukemia; Lymphocyte Activation; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Membrane Proteins; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein Structure, Tertiary; Pyrimidines; Receptors, Antigen, T-Cell; Receptors, Interleukin-2; Sequence Homology, Nucleic Acid; Signal Transduction; Stem Cell Transplantation; Transplantation, Homologous; Up-Regulation; ZAP-70 Protein-Tyrosine Kinase | 2005 |
Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations. A report of three cases.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow Cells; Chromosome Mapping; Core Binding Factors; DNA Primers; Female; Humans; Imatinib Mesylate; Leukemia; Male; Middle Aged; Mutation; Neoplasm Proteins; Piperazines; Polymerase Chain Reaction; Proto-Oncogene Proteins c-kit; Pyrimidines; Transcription Factors | 2005 |
Characteristic of two mouse bcr-abl-transformed cell lines: I. General properties of the cells.
Topics: Animals; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Cell Line, Transformed; Cell Proliferation; Cell Shape; Cell Transformation, Neoplastic; Cellular Senescence; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Histocompatibility Antigens Class I; Imatinib Mesylate; Leukemia; Mice; Mice, Inbred BALB C; Neoplasm Invasiveness; Neoplasm Transplantation; Piperazines; Pyrimidines | 2005 |
Can application of serine protease inhibitors TPCK and TLCK provide evidence for possible involvement of serine protease Omi/HtrA2 in imatinib mesylate-induced cell death of BCR-ABL-positive human leukemia cells?
Topics: Benzamides; High-Temperature Requirement A Serine Peptidase 2; Humans; Imatinib Mesylate; Leukemia; Mitochondrial Proteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Serine Endopeptidases; Serine Proteinase Inhibitors; Tosyllysine Chloromethyl Ketone; Tosylphenylalanyl Chloromethyl Ketone; Tumor Cells, Cultured | 2005 |
The rationale engineering of BCR/ABL blockers: an answer to STI571 acquired resistance in leukemia treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; DNA; DNA Repair; Drug Design; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Triazenes | 2005 |
Relative importance of apoptosis and cell cycle blockage in the synergistic effect of combined R115777 and imatinib treatment in BCR/ABL-positive cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blast Crisis; Cell Cycle; Cell Line, Tumor; Drug Resistance; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Growth Inhibitors; Humans; Imatinib Mesylate; Leukemia; Piperazines; Pyrimidines; Quinolones | 2005 |
NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia.
Topics: Animals; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Genes, abl; Humans; Imatinib Mesylate; Leukemia; Mice; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases | 2005 |
The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.
Topics: Animals; Antineoplastic Agents; Benzamides; Blast Crisis; Cell Line, Transformed; Chromosomal Proteins, Non-Histone; Colforsin; DNA-Binding Proteins; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Histone Chaperones; Humans; Imatinib Mesylate; In Vitro Techniques; K562 Cells; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, SCID; Neoplasm Transplantation; Phosphoprotein Phosphatases; Piperazines; Protein Phosphatase 2; Pyrimidines; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2005 |
Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.
Topics: Adamantane; Apoptosis; Benzamides; Cell Line, Tumor; Clone Cells; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Hydroquinones; Imatinib Mesylate; Leukemia; Mutation; Oxidative Stress; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Reactive Oxygen Species | 2006 |
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells.
Topics: Animals; Apoptosis; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Imatinib Mesylate; Indoles; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Panobinostat; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tumor Cells, Cultured | 2006 |
In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations.
Topics: Administration, Oral; Animals; Benzamides; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Phosphorylation; Piperazines; Pyrimidines; src-Family Kinases; Structure-Activity Relationship; Survival Rate; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2006 |
The effect of prior exposure to imatinib on transplant-related mortality.
Topics: Adolescent; Adult; Benzamides; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia; Male; Middle Aged; Mortality; Piperazines; Pyrimidines; Retrospective Studies; Treatment Outcome | 2006 |
Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Benzoquinones; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Lactams, Macrocyclic; Leukemia; Piperazines; Pyrimidines; Quinones; Rifabutin; Sensitivity and Specificity; Structure-Activity Relationship; Time Factors; Tumor Cells, Cultured | 2006 |
Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.
Topics: Animals; Benzamides; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia; Mice; Mice, Knockout; Mutation; Neoplasm Transplantation; Piperazines; Pyrimidines; Survival Rate; Tumor Suppressor Protein p53 | 2006 |
[Cytotoxic activities of Celecoxib on leukemic cells and the synergistic effects of Celecoxib with Imatinib thereupon].
Topics: Apoptosis; Benzamides; Celecoxib; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Drug Synergism; Humans; Imatinib Mesylate; K562 Cells; Leukemia; Piperazines; Pyrazoles; Pyrimidines; Sulfonamides | 2006 |
Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Cytarabine; Depsipeptides; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Imatinib Mesylate; Irinotecan; K562 Cells; Leukemia; Lymphoma; Mercaptopurine; Piperazines; Pyrimidines; Time Factors | 2007 |
Treating imatinib-resistant leukemia: the next generation targeted therapies.
Topics: Antineoplastic Agents; Benzamides; Drug Delivery Systems; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia; Mutation; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines | 2006 |
Synergistic and additive antiproliferative effects on human leukemia cell lines induced by combining acetylenehexacarbonyldicobalt complexes with the tyrosine kinase inhibitor imatinib.
Topics: Benzamides; Cell Line, Tumor; Cell Proliferation; Cobalt; Drug Screening Assays, Antitumor; Drug Synergism; HL-60 Cells; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia; Molecular Structure; Organometallic Compounds; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2006 |
Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Proliferation; Down-Regulation; Drug Delivery Systems; Drug Synergism; Eukaryotic Translation Initiation Factor 5A; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia; Lysine; Peptide Initiation Factors; Piperazines; Protein Processing, Post-Translational; Proteomics; Pyrimidines; RNA-Binding Proteins | 2007 |
Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias.
Topics: Animals; Apoptosis; Benzamides; Cell Line; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia; Male; Mice; Models, Biological; Phosphotyrosine; Piperazines; Pyrimidines; Xenograft Model Antitumor Assays | 2007 |
Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells.
Topics: Adaptor Proteins, Signal Transducing; Adoptive Transfer; Animals; B-Lymphocytes; Benzamides; Cell Differentiation; Cell Line; Cell Proliferation; DNA-Binding Proteins; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Intercellular Signaling Peptides and Proteins; Intracellular Signaling Peptides and Proteins; Leukemia; Mice; Mice, Inbred BALB C; Mice, Knockout; Oxazines; Phospholipase C gamma; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-myc; Pyridines; Pyrimidines; Receptors, Antigen, B-Cell; Spleen; Syk Kinase; Transfection | 2006 |
Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzamides; Cell Adhesion; Drug Resistance, Neoplasm; Fibronectins; Flavonoids; Humans; Imatinib Mesylate; Integrin beta1; K562 Cells; Leukemia; Membrane Proteins; Mitogen-Activated Protein Kinases; Neoplasm, Residual; Piperazines; Proto-Oncogene Proteins; Pyrimidines; RNA Interference; RNA, Small Interfering | 2007 |
Leukaemia stem cells: hit or miss?
Topics: Benzamides; Cell Differentiation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia; Neoplastic Stem Cells; Piperazines; Pyrimidines; Time Factors | 2007 |
Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line; Drug Synergism; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia; Male; Mice; Models, Biological; Phosphotyrosine; Piperazines; Pyrimidines; Xenograft Model Antitumor Assays | 2007 |
Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells.
Topics: Acid Anhydride Hydrolases; Animals; Antineoplastic Agents; Benzamides; Cell Cycle Proteins; Cell Survival; DNA Repair; DNA Repair Enzymes; DNA Replication; DNA-Binding Proteins; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia; Mice; MRE11 Homologue Protein; Nuclear Proteins; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Recombination, Genetic | 2007 |
The immunogenicity of Bcr-Abl expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl regulated antigens.
Topics: Animals; Antigens; Benzamides; CD8-Positive T-Lymphocytes; Dendritic Cells; Enzyme Activation; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; HLA Antigens; Humans; Imatinib Mesylate; Immunogenetics; Leukemia; Lymphocyte Activation; Piperazines; Pyrimidines; Up-Regulation; Xenopus laevis | 2007 |
Hemin reduces cellular sensitivity to imatinib and anthracyclins via Nrf2.
Topics: Anthracyclines; Benzamides; Cell Line, Tumor; Drug Interactions; Drug Resistance; Hemin; Humans; Imatinib Mesylate; Leukemia; NF-E2-Related Factor 2; Piperazines; Pyrimidines; Up-Regulation | 2008 |
RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blast Crisis; Chromosomes, Human; Chronic Disease; Core Binding Factor Alpha 2 Subunit; Disease-Free Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Phenotype; Piperazines; Point Mutation; Pyrimidines; Retrospective Studies; Survival Rate; Transcription Factors; Translocation, Genetic; Trisomy | 2008 |
Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry.
Topics: Antineoplastic Agents; Benzamides; Chromatography, Liquid; Humans; Imatinib Mesylate; Leukemia; Piperazines; Pyrimidines; Tandem Mass Spectrometry | 2008 |
Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
Topics: Anilides; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Leukemia; Mice; Neoplasm Transplantation; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-abl; Pyrimidines | 2008 |
Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin.
Topics: Apoptosis; Benzamides; Benzoquinones; Blast Crisis; Caspase 3; Caspase 9; Cell Proliferation; Cytochromes c; Extracellular Signal-Regulated MAP Kinases; Fusion Proteins, bcr-abl; HL-60 Cells; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Immunoprecipitation; K562 Cells; Lactams, Macrocyclic; Leukemia; Novobiocin; Piperazines; Proteasome Endopeptidase Complex; Pyrimidines | 2008 |
Hematologic malignancies: selected abstracts and commentary.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Immunoconjugates; Leukemia; Lymphoma; Piperazines; Pyrimidines | 2000 |
CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Differentiation; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia; Piperazines; Pyrimidines | 2000 |
New therapies show promise for patients with leukemia, hemophilia, and heart disease.
Topics: Animals; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Genetic Therapy; Heart Diseases; Hematopoietic Stem Cell Transplantation; Hemophilia A; Humans; Imatinib Mesylate; Leukemia; Piperazines; Pyrimidines | 2001 |
Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Benzamides; Blotting, Western; Cytochrome c Group; Drug Combinations; Drug Synergism; Genes, abl; Humans; Imatinib Mesylate; Leukemia; Ligands; Membrane Glycoproteins; Piperazines; Pyrimidines; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2001 |
In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cytarabine; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Harringtonines; Homoharringtonine; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Microbial Sensitivity Tests; Neoplasm Proteins; Neoplasms; Piperazines; Pyrimidines; Tumor Cells, Cultured; Vincristine | 2001 |
Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Division; DNA Damage; DNA, Neoplasm; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Janus Kinase 2; K562 Cells; Leukemia; Neoplasm Proteins; Phosphorylation; Piperazines; Protein Processing, Post-Translational; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrimidines; Recombinant Fusion Proteins; Signal Transduction; Transfection; Tumor Cells, Cultured; Tyrphostins | 2001 |
Leukemia cells fall on their swords.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Fatty Acids, Unsaturated; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Translocation, Genetic | 2001 |
Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Benzamides; Drug Synergism; Fusion Proteins, bcr-abl; Hemoglobins; Humans; Imatinib Mesylate; Leukemia; Macrophage-1 Antigen; Oxides; Piperazines; Protein Serine-Threonine Kinases; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein | 2001 |
Treatment of leukemia relapse after allogeneic hematopoietic stem cell transplantation by donor lymphocyte infusion and STI-571.
Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia; Lymphocyte Transfusion; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Transplantation, Homologous; Treatment Outcome | 2001 |
[The tyrosine kinase antagonist imatinib mesylate].
Topics: Animals; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2002 |
Decrease of resistance to imatinib in leukaemia.
Topics: Benzamides; Biological Availability; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia; Piperazines; Pyrimidines | 2002 |
ABL-specific tyrosine kinase inhibitor imatinib as salvage therapy in a child with Philadelphia chromosome-positive acute mixed lineage leukemia (AMLL).
Topics: Acute Disease; Antineoplastic Agents; Benzamides; Cell Lineage; Child; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia; Male; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Salvage Therapy | 2002 |